NTLA Intellia Therapeutics, Inc.

Price (delayed)

$39.26

Market cap

$2.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$2.16B

Sector: Healthcare
Industry: Biotechnology
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Highlights

The gross profit has soared by 56% YoY and by 23% from the previous quarter
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The company's debt rose by 13% YoY but it fell by 4.2% QoQ
The net income has contracted by 33% YoY and by 3.6% from the previous quarter
The EPS has contracted by 16% YoY

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
59.08M
Market cap
$2.32B
Enterprise value
$2.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7
Price to sales (P/S)
37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.68
Earnings
Revenue
$62.34M
EBIT
-$120.32M
EBITDA
-$114.02M
Free cash flow
-$43.5M
Per share
EPS
-$2.29
Free cash flow per share
-$0.74
Book value per share
$5.61
Revenue per share
$1.06
TBVPS
$7.8
Balance sheet
Total assets
$458.56M
Total liabilities
$128.94M
Debt
$22.2M
Equity
$329.62M
Working capital
$360.39M
Liquidity
Debt to equity
0.07
Current ratio
7.45
Quick ratio
7.32
Net debt/EBITDA
1.38
Margins
EBITDA margin
-182.9%
Gross margin
100%
Net margin
-193%
Operating margin
-198.9%
Efficiency
Return on assets
-30.1%
Return on equity
-40.1%
Return on invested capital
-58.6%
Return on capital employed
-29.9%
Return on sales
-193%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-0.3%
1 week
14.53%
1 month
63.99%
1 year
126.54%
YTD
167.62%
QTD
97.48%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$62.34M
Gross profit
$62.34M
Operating income
-$123.96M
Net income
-$120.32M
Gross margin
100%
Net margin
-193%
The gross profit has soared by 56% YoY and by 23% from the previous quarter
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ
The net income has contracted by 33% YoY and by 3.6% from the previous quarter
The company's operating income fell by 27% YoY and by 2.3% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
7
P/S
37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.68
The EPS has contracted by 16% YoY
The stock's P/B is 141% above its last 4 quarters average of 2.9 and 126% above its 5-year quarterly average of 3.1
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The price to sales (P/S) is 110% higher than the last 4 quarters average of 17.6 and 38% higher than the 5-year quarterly average of 26.8
Intellia Therapeutics's revenue has surged by 56% YoY and by 23% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
Intellia Therapeutics's ROIC has plunged by 79% YoY and by 9% from the previous quarter
Intellia Therapeutics's ROE has decreased by 22% YoY
The ROA has contracted by 16% YoY but it has grown by 3.5% from the previous quarter
The ROS has grown by 16% from the previous quarter and by 14% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has surged by 82% YoY but it has decreased by 7% QoQ
The total assets has grown by 32% YoY but it has contracted by 7% from the previous quarter
The company's debt is 93% lower than its equity
Intellia Therapeutics's equity has increased by 20% YoY but it has decreased by 6% from the previous quarter
The company's debt rose by 13% YoY but it fell by 4.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.